Chemistry:Tanaproget
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C16H15N3OS |
| Molar mass | 297.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tanaproget (INN; developmental code names NSP-989, WAY-166989) is an investigational nonsteroidal progestin.[1] It is a high affinity, high efficacy, and very selective agonist of the progesterone receptor (PR).[1] Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison.[1] As of December 2010,[2] it is in phase II clinical trials in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.[3][4]
An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.[5]
See also
References
- ↑ 1.0 1.1 1.2 "Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget". J. Biol. Chem. 280 (31): 28468–75. August 2005. doi:10.1074/jbc.M504144200. PMID 15937332.
- ↑ Tanaproget
- ↑ "Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women". Contraception 74 (5): 414–8. November 2006. doi:10.1016/j.contraception.2006.06.004. PMID 17046384.
- ↑ "Gateways to clinical trials". Methods Find Exp Clin Pharmacol 27 (7): 505–22. September 2005. PMID 16258596.
- ↑ "Development of [F-18]fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography". Bioconjug. Chem. 21 (6): 1096–104. June 2010. doi:10.1021/bc1001054. PMID 20496889.
 |  |
